Filorexant

Last updated
Filorexant
Filorexant.svg
Clinical data
Other namesMK-6096; MK6096
Routes of
administration 		By mouth
Drug class Orexin antagonist
ATC code
  • None
Pharmacokinetic data
Elimination half-life 3–6 hours [1]
Identifiers
  • [(2R,5R)-5-{[(5-Fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.203.042 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C24H25FN4O2
Molar mass 420.488 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F
  • InChI=1S/C24H25FN4O2/c1-16-4-8-20(23-26-10-3-11-27-23)21(12-16)24(30)29-14-18(6-5-17(29)2)15-31-22-9-7-19(25)13-28-22/h3-4,7-13,17-18H,5-6,14-15H2,1-2H3/t17-,18-/m1/s1
  • Key:NPFDWHQSDBWQLH-QZTJIDSGSA-N

Filorexant (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Approved Name; developmental code name MK-6096) is an orexin antagonist which was under development by Merck for the treatment of insomnia, depression, diabetic neuropathy, and migraine. [2] [3] It is a dual antagonist of the orexin OX1 and OX2 receptors. [4] [5] It has a relatively short elimination half-life of 3 to 6 hours. [1] However, it dissociates slowly from the orexin receptors and may thereby have a longer duration. [6] Possibly in relation to this, filorexant shows next-day somnolence similarly to suvorexant. [6] In phase 2 clinical trials, filorexant was found to be effective in the treatment of insomnia, [7] but was not effective in the treatment of major depressive disorder, [8] [9] [10] painful diabetic neuropathy, [11] [12] or migraine. [13] As of May 2015, filorexant was no longer listed on Merck's online development pipeline and hence development of the drug appears to have been discontinued. [14] [1] [2] Development of filorexant may have been discontinued due to lack of differentiation from suvorexant (which was also developed by Merck). [6]

Contents

See also

References

  1. 1 2 3 Hoyer D, Jacobson LH (13 November 2017). "Orexin Receptor Antagonists". Current Sleep Medicine Reports. 3 (4): 342–353. doi:10.1007/s40675-017-0099-7. eISSN   2198-6401. hdl: 11343/282828 . S2CID   80067706.
  2. 1 2 "Filorexant". AdisInsight. Springer Nature Switzerland AG.
  3. ↑ Hoyer D, Jacobson LH (December 2013). "Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?". Neuropeptides. 47 (6): 477–488. doi:10.1016/j.npep.2013.10.009. PMID   24215799. S2CID   6402764.
  4. ↑ Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, et al. (February 2012). "Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia". Neuropharmacology. 62 (2): 978–987. doi:10.1016/j.neuropharm.2011.10.003. PMID   22019562. S2CID   35304627.
  5. ↑ Peroutka SJ (January 2014). "Clinical trials update. 2013: year in review". Headache. 54 (1): 189–194. doi:10.1111/head.12267. PMID   24400767. S2CID   28141555.
  6. 1 2 3 Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine. 291 (5): 533–556. doi:10.1111/joim.13406. PMID   35043499. S2CID   248119793.
  7. ↑ Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, et al. (August 2016). "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia". The International Journal of Neuropsychopharmacology. 19 (8): pyw022. doi:10.1093/ijnp/pyw022. PMC   5006195 . PMID   26979830.
  8. ↑ Summers CH, Yaeger JD, Staton CD, Arendt DH, Summers TR (March 2020). "Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy". Brain Research. 1731: 146085. doi:10.1016/j.brainres.2018.12.036. PMC   6591110 . PMID   30590027.
  9. ↑ Han Y, Yuan K, Zheng Y, Lu L (April 2020). "Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders". Neuroscience Bulletin. 36 (4): 432–448. doi:10.1007/s12264-019-00447-9. PMC   7142186 . PMID   31782044.
  10. ↑ Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, et al. (August 2017). "Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder". The International Journal of Neuropsychopharmacology. 20 (8): 613–618. doi:10.1093/ijnp/pyx033. PMC   5570043 . PMID   28582570.
  11. ↑ Steiner MA, Winrow CJ (11 November 2014). Insomnia and beyond - Exploring the therapeutic potential of orexin receptor antagonists. Frontiers E-books. pp. 3–. ISBN   978-2-88919-330-1.
  12. ↑ Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D (January 2018). "Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant". The Clinical Journal of Pain. 34 (1): 37–43. doi:10.1097/AJP.0000000000000503. PMID   28448426. S2CID   23060776.
  13. ↑ Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, et al. (April 2015). "Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis". Cephalalgia. 35 (5): 379–388. doi:10.1177/0333102414544979. PMID   25106663. S2CID   20872932.
  14. ↑ "Merck Pipeline". Merck. 2015. Retrieved 2015-05-14.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.